Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Raffi

Showing results (221-230 of 224) with videos related to

Pageof 23
Sort By:
You have reached the last page of results.This site can display upto 224 results.
HIV Medicine|August 9, 2011
Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patientsS M E Vrouenraets, F W N M Wit, E Fernandez Garcia, et al.
Lancet (London, England)|April 20, 2004
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN StudyF van Leth, P Phanuphak, K Ruxrungtham, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 8, 2013
The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy eraA Mocroft, H J Furrer, J M Miro, et al.
HIV Medicine|December 8, 2017
Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study)E Rosenthal, C Fougerou-Leurent, A Renault, et al.
Pageof 23

Showing results (221-230 of 224) with videos related to

Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 224 results.
HIV Medicine|August 9, 2011
Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patientsS M E Vrouenraets, F W N M Wit, E Fernandez Garcia, et al.
Lancet (London, England)|April 20, 2004
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN StudyF van Leth, P Phanuphak, K Ruxrungtham, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 8, 2013
The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy eraA Mocroft, H J Furrer, J M Miro, et al.
HIV Medicine|December 8, 2017
Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study)E Rosenthal, C Fougerou-Leurent, A Renault, et al.
Pageof 23